Tactile Systems Tech stock (US87874P1012): CFO sells $113K in shares

Tactile Systems Technology CFO sold $113,403 in TCMD stock recently, amid recent earnings beat with EPS of -$0.08 vs. -$0.11 expected and $75.3M revenue. Stock trades at $23.53 on Nasdaq.

Tactile Systems Technology, a medical device firm focused on at-home therapies, saw its CFO sell shares worth $113,403 in common stock, according to a filing reported by Investing.com as of May 2026. The transaction occurred as the company reported stronger-than-expected Q1 results, with EPS of -$0.08 beating consensus estimates of -$0.11 and revenue reaching $75.3 million.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Tactile Systems Technology Inc
• Sector/industry: Medical Devices
• Headquarters/country: United States
• Core markets: US healthcare, lymphedema therapy
• Key revenue drivers: At-home medical devices
• Home exchange/listing venue: Nasdaq (TCMD)
• Trading currency: USD

Tactile Systems Tech: core business model

Tactile Systems Technology develops and markets medical devices for chronic conditions, primarily focusing on lymphedema, venous insufficiency, and respiratory failure. The company's flagship products include the Flexitouch and Entre systems for at-home compression therapy, which help patients manage swelling without frequent clinical visits. These devices are prescribed by physicians and reimbursed by US payers including Medicare, making them accessible to a broad patient base in the US healthcare system.

Listed on Nasdaq under ticker TCMD (ISIN US87874P1012), Tactile Systems Tech emphasizes patient-centric innovation, with a direct-to-consumer sales model supported by clinical specialists. The firm reported a market cap of approximately $530.75 million as of recent data from WallStreetZen in 2026.

Main revenue and product drivers for Tactile Systems Tech

Revenue primarily stems from sales of compression therapy devices and related garments, with the lymphedema segment accounting for the majority. In the latest quarter, the company posted $75.3 million in revenue alongside an EPS of -$0.08, surpassing analyst expectations of -$0.11, per Investing.com as of May 2026. Key drivers include growing awareness of at-home therapies post-COVID and expanded reimbursement coverage.

The stock has delivered strong performance, returning 135.73% over the past year, outperforming peers in the medical device sector, according to WallStreetZen data for the period ending 2026.

Industry trends and competitive position

The medical device industry, particularly at-home care, benefits from aging US demographics and shifts toward outpatient treatments. Tactile Systems Tech holds a niche leadership in lymphedema management, where competition includes larger players like Tactile's peers in compression tech. Its Zen Rating of A from WallStreetZen ranks it #3 among 139 medical device stocks, with strong due diligence scores in value, safety, and financials.

Why Tactile Systems Tech matters for US investors

As a Nasdaq-listed firm with deep US market exposure via Medicare reimbursements and domestic sales, Tactile Systems Tech offers retail investors access to the growing home healthcare trend. Exposure to US healthcare spending, projected to rise with an aging population, positions it relevant for portfolios tracking medtech innovation.

Conclusion

Tactile Systems Tech continues to navigate insider sales and earnings beats in the competitive medtech space. Recent CFO share disposal follows solid quarterly results, while the stock's 135%+ yearly gain highlights momentum. Investors monitor upcoming catalysts amid sector tailwinds.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.